RE:RE:RE:RE:RE:RE:Antibody-Drug-Conjugate (ADC) company reports patient death August 18, 2023 - Seagen released Phase III results on Wednesday (August 16) for its tyrosine kinase inhibitor Tukysa (tucatinib), in combination with Genentech’s antibody-drug conjugate Kadcyla (ado-trastuzumab emtansine), which met its primary endpoint of progression-free survival in HER-2 positive breast cancer patients.
Serious adverse reactions occurred in the study in 26% of patients, according to Seagen, with the most common being diarrhea, vomiting, nausea, abdominal pain, and seizure. Fatal adverse reactions occurred in 2% of patients receiving Tukysa, including sudden death, sepsis, dehydration, and cardiogenic shock.
Tukysa is a tyrosine kinase inhibitor which works by inhibiting phosphorylation of HER2 and HER3, a well-established biomarker of poor outcomes in gastric, breast, and colon cancers. This results in anti-tumor activity in HER-2 expressing tumor cells.
https://www.biospace.com/article/seagen-touts-phase-iii-data-for-breast-cancer-combo-therapy-/